Indications 

Atelvia DR is a prescribed medication indicated for managing postmenopausal osteoporosis (bone loss). 

As a bisphosphonate, Atelvia DR reduces bone loss by slowing down the activity of osteoclasts, the cells that break down and reabsorb bone. This action helps osteoblasts, the bone-building cells, work better, leading to improved bone density (thickness). 

Uses and Dosage 

Before taking Atelvia DR and with each prescription refill, thoroughly review the accompanying medication guide and patient information leaflet. Should you have any inquiries or concerns, seek guidance from your doctor or pharmacist. 

Atelvia DR is a once-weekly medication taken in the morning, immediately after breakfast. You can select the most convenient day of the week for your schedule and consistently take it on that same day every week. 

Atelvia DR tablet must be taken whole, not cut, crushed, or chewed, with at least 4 ounces of plain water while in an upright position to ensure it reaches the stomach. 

Avoid lying down immediately after ingestion; maintain an upright sitting or standing position for at least 30 minutes. 

Following this medication, refrain from consuming food, beverages, or other medicines for at least 30 minutes. 

To achieve optimal results, follow your doctor’s instructions precisely when taking Atelvia DR. Avoid exceeding or reducing the prescribed dose or frequency of use. 

Keep taking this medication even if you feel well, and periodically discuss the necessity of continued use. 

If you miss a dose of Atelvia DR, do not take it later in the day. Take one dose the morning after you recall, and then resume your regular weekly dosing schedule. 

Side Effects 

Listed below are the potential adverse effects of Atelvia DR. Inform your doctor promptly should any of these symptoms last or worsen. 

Common Side Effects 

• Heartburn, diarrhea, indigestion 
• Stomach pain 
• Back pain, joint pain, muscle pain 
• Flu-like symptoms 

Serious Side Effects 

• Chest pain, new or worsening heartburn 
• Difficulty or pain while swallowing 
• Pain or burning sensations under the ribs or in the back 
• Severe heartburn, burning upper stomach pain, or coughing up blood 
• New or unusual pain in the thigh or hip 
• Jaw pain, numbness, or swelling 
• Severe joint, bone, or muscle pain 
• Low calcium levels, indicated by: 
  • Muscle spasms or contractions 
  • Numbness or tingling (around the mouth, fingers, and toes) 

Stop taking Atelvia DR and call your doctor immediately if you exhibit any of the serious side effects listed above. 

Seek immediate medical assistance if you experience symptoms of a severe skin reaction, such as: 

• Fever 
• Sore throat 
• Eye discomfort 
• Skin pain 
• Development of a spreading rash that results in blistering and peeling 

Allergic Reactions 

In rare cases, Atelvia DR may trigger a serious allergic response. Seek immediate medical help if any signs of an allergic reaction manifest, such as: 

• Face, lips, tongue, or throat swelling 
• Difficulty in breathing 
• Hives 

This list does not cover all side effects of Atelvia DR. Inform your doctor if you experience other effects. 

Cautions 

Before starting treatment with Atelvia DR, inform your doctor of any known allergies, particularly to risedronate. 

For additional details about this medication, consult your pharmacist, as it may contain inactive components that may trigger allergic reactions or other adverse responses. 

To ensure Atelvia DR is safe for you, disclose to your doctor your medical background, especially if you have a history of: 

• Kidney disease 
• Inability to maintain an upright position or stand for 30 minutes 
• Low blood calcium levels (hypocalcemia) 
• Esophageal disorders like stricture or achalasia 
• Difficulty or pain during swallowing 
• Stomach and intestinal disorders, including ulcers 

Medications that reduce stomach acid (e.g., antacids, H2 blockers like ranitidine, proton pump inhibitors like omeprazole) can interact with Atelvia DR.  

To lower the risk of drug interactions with Atelvia DR, inform all your healthcare providers of any current, recently started, or stopped medications, including prescription and over-the-counter drugs, vitamins, and herbal supplements. 

The medications listed below may impede the absorption of risedronate. Take these medicines either at a different time of day from the Atelvia DR dose or wait for at least 30 minutes after taking Atelvia DR before consuming them: 

• Calcium or iron supplements 
• Vitamins containing minerals 
• Products containing calcium/magnesium/aluminum (e.g., antacids, laxatives) 
• Quinapril 
• Specific forms of didanosine (chewable/dispersible buffered tablets or pediatric oral solution) 
• Sucralfate 
• Bismuth subsalicylate 

Avoid smoking or make efforts to quit during treatment with Atelvia DR, as smoking can diminish bone mineral density and increase the risk of fractures. 

Refrain from consuming excessive alcohol while taking Atelvia DR, as heavy drinking can contribute to bone loss. 

Atelvia DR can potentially affect laboratory tests, such as bone-imaging tests, leading to inaccurate results. Ensure that laboratory staff and your healthcare providers are informed of your use of this medication. 

Atelvia DR may carry a risk of jawbone issues (osteonecrosis), which is most elevated in individuals with conditions like cancer, blood disorders, pre-existing dental problems, or those undergoing treatment with steroids, chemotherapy, or radiation. Consult your healthcare provider to assess your specific risk. 

Talk to your dentist and doctor if you require dental surgery or tooth extraction and have been on Atelvia DR long-term. They may advise discontinuation of this medication. 

Inform your doctor of your current pregnancy status and any plans for future pregnancies, as risedronate can persist in the body for several years after discontinuation. Contact your doctor immediately if you become pregnant either during or after your course of treatment with Atelvia DR. 

Seek guidance from your healthcare provider before breastfeeding, as the transfer of risedronate into breast milk is not well understood.